Supplementary materials: Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis
These are peer-reviewed supplementary materials for the article 'Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis' published in the Journal of Comparative Effectiveness Research.
- Supplementary figure 1
- Supplementary figure 2
- Supplementary figure 3
- Supplementary figure 4
- Supplementary figure 5
- Supplementary figure 6
- Supplementary figure 7
- Supplementary table 1
Aim: 20 mg of vonoprazan (VPZ20) is recommended in most countries to treat erosive esophagitis (EE). Whether other doses of vonoprazan, such as 5 mg (VPZ5), 10 mg (VPZ10), 20 mg (VPZ20), and 40 mg (VPZ40) are more effective is unknown. Materials & methods: Three databases were electronically searched to identify studies published before November 2021. Network meta-analysis was performed using STATA 14.0. Results: VPZ20 and VPZ40 were comparable to PPI, VPZ5 and VPZ10 in 4- and 8-week healing rates, and this was also detected in patients with refractory EE. All regimens resulted in similar treatment-emergent adverse events (TEAEs). However, VPZ40 ranked first for healing rate and TEAEs; however, VPZ20 ranked worst for TEAEs. Conclusion: Different doses of VPZ are comparable in efficacy and safety, but VPZ40 may be best in both effectiveness and safety.
